Company Overview
Aeterna Zentaris is focused on serving the unmet medical needs of patients with rare endocrine diseases through acquisition, development and licensing orphan products. Our vision for the future focuses on leveraging our global endocrinology expertise acquired through clinical development of macimorelin to establish a value driven product portfolio for endocrinology orphan diseases through acquisition of marketed and development-stage medicines and/or in- and out-licensing activities. Our business development team is constantly looking for new opportunities to make strategic deals that benefit our patients, our partners and our shareholders.